Literature DB >> 9756203

Expression of two isoforms of Lep d 2, the major allergen of Lepidoglyphus destructor, in both prokaryotic and eukaryotic systems.

S Olsson1, M van Hage-Hamsten, P Whitley, E Johansson, D R Hoffman, G Gafvelin, M Schmidt.   

Abstract

BACKGROUND: The dust mite Lepidoglyphus destructor is a major cause of allergic diseases among farmers. We have previously cloned and sequenced two isoforms of the major allergen Lep d 2 (formerly designated Lep d 1) and found significant homology to group 2 allergens of the house dust mite species Dermatophagoides. We now report on the production and characterization of recombinant Lep d 2.
OBJECTIVE: We have expressed both isoforms in two different expression systems; a eukaryotic system, baculovirus in insect cells and a prokaryotic system, E. coli. We have compared the two systems in regard to production yields and immunoreactivity of the recombinant allergens.
METHODS: The complete cDNA including the natural leader sequence was cloned into the pBlueBacIII transfer vector, and the rLep d 2 was produced as a secreted protein in baculovirus. For the expression in E. coli, the cDNA was cloned into the pET vector, and the rLep d 2 was produced with six C-terminal histidine residues. The purified recombinant allergens were tested for immunoreactivity with 10 sera from subjects allergic to Lepidoglyphus destructor and were compared with native Lep d 2 using inhibition immunoblotting. The ability of the recombinant allergens to release histamine from basophils was evaluated using a histamine release assay.
RESULTS: Both expression systems produced immunoreactive recombinant allergens. They inhibited the binding of human sera to native Lep d 2 confirming their retained IgE binding properties. The yield of pure recombinant protein from the prokaryotic system was approximately 1 mg/L compared to the eukaryotic system which produced up to 4 mg/L in an adherent cell culture system.
CONCLUSIONS: We have produced recombinant Lep d 2 in prokaryotic and eukaryotic expression systems which are comparable to the native allergen. Recombinant Lep d 2 might now be included in more extensive clinical studies to confirm its usefulness in the in vitro and the in vivo diagnosis of Lepidoglyphus destructor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756203     DOI: 10.1046/j.1365-2222.1998.00375.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

1.  Immunological characterization of the American cockroach allergen Per a 9 expressed in baculovirus-infected insect cells.

Authors:  Hai-Wei Yang; Wei Zhang; Wei-Wei Ni; Min Jin; Shao-Heng He; Ji-Fu Wei
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

2.  Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis.

Authors:  Jacob Glenting; Lars K Poulsen; Kentaro Kato; Søren M Madsen; Hanne Frøkiær; Camilla Wendt; Helle W Sørensen
Journal:  Microb Cell Fact       Date:  2007-08-21       Impact factor: 5.328

3.  Preparation and identification of Per a 5 as a novel American cockroach allergen.

Authors:  Ji-Fu Wei; Haiwei Yang; Dongning Li; Peisong Gao; Shaoheng He
Journal:  Mediators Inflamm       Date:  2014-02-23       Impact factor: 4.711

4.  Group 1 Allergen Genes in Two Species of House Dust Mites, Dermatophagoides farinae and D. pteronyssinus (Acari: Pyroglyphidae): Direct Sequencing, Characterization and Polymorphism.

Authors:  Rubaba Hamid Shafique; Pavel B Klimov; Muhammad Inam; Farhana Riaz Chaudhary; Barry M OConnor
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

Review 5.  Consideration of methods for identifying mite allergens.

Authors:  Yubao Cui; Qiong Wang; Haoyuan Jia
Journal:  Clin Transl Allergy       Date:  2018-04-27       Impact factor: 5.871

6.  Expression of recombinant allergen, Der f 1, Der f 2 and Der f 4 using baculovirus-insect cell systems.

Authors:  Yubao Cui; Lili Yu; Feixiang Teng; Nan Wang; Ying Zhou; Chengbo Zhang; Li Yang
Journal:  Arch Med Sci       Date:  2018-10-23       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.